<DOC>
	<DOCNO>NCT02289547</DOCNO>
	<brief_summary>XELOX regimen favorable toxicity profile compare cisplatin patient advance gastric cancer . The safety profile oxaliplatin make ideal candidate combination therapy . However , oxaliplatin induce sensory neuropathy , cumulative , dose-related toxicity . It may therefore possible devise capecitabine maintenance regimen achieve maximum treatment effect cumulative neurotoxicity appear . We study randomized Phase III study Xelox ( Capecitabine plus Oxaliplatin ) follow maintenance Capecitabine Observation gastric cancer patient stable disease 6 cycle 1st line XELOX chemotherapy .</brief_summary>
	<brief_title>Phase 3 Study Xelox Followed Maintenance Capecitabine Advanced Gastric Cancer</brief_title>
	<detailed_description>Study rationale : Park et al . observe oxaliplatin part XELOX regimen favorable toxicity profile compare cisplatin patient advance gastric cancer . The safety profile oxaliplatin make ideal candidate combination therapy . However , oxaliplatin induce sensory neuropathy , cumulative , dose-related toxicity . The response XELOX regimen generally occur earlier . It may therefore possible devise capecitabine maintenance regimen achieve maximum treatment effect cumulative neurotoxicity appear . This regimen study colon breast cancer . - Objective : Primary : To evaluate progression free survival Secondary : To evaluate overall survival , response rate , toxicity profile chemotherapy , quality life - Design : Multicenter randomize controlled phase III open label trial Study subject randomize two group ratio 1:1 Subjects More stable disease 6 cycle 1st line XELOX chemotherapy ( OR non-complete response/non-progressive disease case non-measurable disease XELOX chemotherapy ) , - Treatment Groups Group A : Capecitabine : Capecitabine 1000mg/m2 bid D1-14 , q 3 week Group B : Observation - Evaluation response toxicity A response evaluate radiologically every two cycle thereafter , progression suspicious RECIST criterion version 1.1 . A progression-free survival define time date randomization date first document disease progression death due cause . An overall survival define time 1stdate chemotherapy date death . Safety evaluate every treatment NCI-CTCAE version 4.0 .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Histologically proven gastric cancer Minimum age 18 year Stage IV ( regardless presence absence measurable disease RECIST criterion ) recurrent curative surgery Negative expression ( 0 , 1 ) Her2 Immunohistochemistry negative amplification FISH Her2 Immunohistochemistry 2+ More stable disease 6 cycle 1st line XELOX chemotherapy ( OR nonComplete response/nonProgressive disease case nonmeasurable disease XELOX chemotherapy ) Eastern Cooperative Oncology Group Performance status 02 Adequate bone marrow function : Absolute neutrophil count ≥ 1,500/ul , Hemoglobin ≥ 8 g/dL , platelet ≥ 100,000/μl Adequate renal function : Serum creatinine ≤ 1.5 x ULN ( upper normal limit ) creatinine clearance ≥ 60 ml/min Adequate hepatic function : serum bilirubin ≤ 2.5 x UNL , AST ALT ≤ 2.5 x UNL ( ≤ 5 x ULN presence liver metastasis ) Patients must sign informed consent indicate aware investigational nature study keep policy hospital Patients expose previously chemotherapy except XELOX advance disease Patients receive R0 R1 resection metastatic recurrent gastric cancer without evaluable/measurable disease Disease relapse within 4 month adjuvant therapy Patients central nervous system meningeal metastases Patients significant neurologic psychiatric disorder Patients active infection , severe heart disease , uncontrollable hypertension diabetes mellitus , myocardial infarction precede 6 month , pregnancy , breast feeding Any previous concurrent malignancy except adequately treat nonmelanoma skin cancer , situ cancer uterine cervix , nonmuscle invasive bladder cancer malignancy without evidence recurrence within 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>chemotherapy</keyword>
	<keyword>stomach neoplasm</keyword>
</DOC>